Abstract
Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have